Pfizer's breast cancer drug Ibrance fails late-stage study

Pfizer Inc said on Friday its cancer drug Ibrance did not meet the main goal in a late-stage trial in patients with a type of breast cancer, the latest setback in the company’s attempt to expand the use of the drug to treat early stages of the disease.